Ovarian carcinoma (high-grade serous predominant) · line 3 · None
Deterministic view of the source YAML entity. Clinical authority remains with the cited source IDs and reviewer sign-off state.
Knowledge-base record for audit. Provisional clinical content: this is not a prescription. An oncologist must verify original sources, applicability and review status. Full rules and constraints are in the YAML.
| Line of therapy | 3 |
|---|---|
| Track | standard |
| Linked regimen | None |
| ID | IND-OVARIAN-3L-POST-PARPi-POST-MIRVE |
|---|---|
| Type | Indication |
| Status | reviewed 2026-04-27 | pending_clinical_signoff |
| Diseases | DIS-OVARIAN |
| Sources | SRC-ESMO-OVARIAN-2024 SRC-NCCN-OVARIAN-2025 SRC-OVA-301-MONK-2010 |
Notes
STUB — pending Clinical Co-Lead sign-off. 3L+ pathway for platinum-resistant ovarian after PARPi + mirvetuximab exhaustion. Multiple sequential single-agent chemo options exist; treatment selection highly individualized. Missing entity flag: dedicated REG-PLD-MONO + REG-WEEKLY-PACLITAXEL-OVARIAN + REG-TRABECTEDIN-PLD — author in PROD-2.
Used By
No reverse references found in the YAML corpus.